share_log

復星醫藥：海外監管公告 - 關於控股子公司獲藥品註冊批准的公告

FOSUN PHARMA: Overseas Regulatory Announcement - Announcement in Relation to the Approval for Drug Registration of a Subsidiary

HKEX ·  Jun 27 21:24
Summary by Futu AI
上海復星醫藥（集團）股份有限公司（簡稱「復星醫藥」）宣布其控股子公司重慶藥友製藥有限責任公司自主研發的注射用尼可地爾新藥，用於治療不穩定型心絞痛，已於近日獲得國家藥品監督管理局的上市註冊批准。該新藥的研發至2024年5月累計投入約人民幣446萬元（未經審計）。根據IQVIA CHPA的數據，2023年注射用尼可地爾在中國境內的銷售額約為人民幣7.85億元。復星醫藥預計該新藥的上市不會對集團當前業績產生重大影響，但提醒投資者注意由於市場競爭等因素，新藥的具體銷售情況存在不確定性，並應當意識到相關的投資風險。
上海復星醫藥（集團）股份有限公司（簡稱「復星醫藥」）宣布其控股子公司重慶藥友製藥有限責任公司自主研發的注射用尼可地爾新藥，用於治療不穩定型心絞痛，已於近日獲得國家藥品監督管理局的上市註冊批准。該新藥的研發至2024年5月累計投入約人民幣446萬元（未經審計）。根據IQVIA CHPA的數據，2023年注射用尼可地爾在中國境內的銷售額約為人民幣7.85億元。復星醫藥預計該新藥的上市不會對集團當前業績產生重大影響，但提醒投資者注意由於市場競爭等因素，新藥的具體銷售情況存在不確定性，並應當意識到相關的投資風險。
Fosun Pharma, based in Shanghai, announced that its subsidiary Chongqing Pharmaceutical Research Institute has obtained approval from the National Medical Products Administration for a new injectable drug Nicorandil for the treatment of unstable angina pectoris, which was independently developed by the company. The development of the new drug has invested approximately CNY 4.46 million (unaudited) by May 2024. According to data from IQVIA CHPA, the sales of Nicorandil for injection in China are estimated to be approximately CNY 785 million in 2023. Fosun Pharma expects that the launch of the new drug will not have a significant impact on the group's current performance, but reminds investors to be aware of the investment risks associated with the specific sales situation of the new drug due to market competition and other factors.
Fosun Pharma, based in Shanghai, announced that its subsidiary Chongqing Pharmaceutical Research Institute has obtained approval from the National Medical Products Administration for a new injectable drug Nicorandil for the treatment of unstable angina pectoris, which was independently developed by the company. The development of the new drug has invested approximately CNY 4.46 million (unaudited) by May 2024. According to data from IQVIA CHPA, the sales of Nicorandil for injection in China are estimated to be approximately CNY 785 million in 2023. Fosun Pharma expects that the launch of the new drug will not have a significant impact on the group's current performance, but reminds investors to be aware of the investment risks associated with the specific sales situation of the new drug due to market competition and other factors.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.